MDL-27531

• Description :

  MDL-27531 acts functionally like a glycine agonist. MDL-27531 selectively reduces hindlimb contractions. MDL-27531 selectively reverses strychnine-induced seizures in mice. MDL-27531 inhibits pentylenetetrazol-induced seizures with an ED50 of 55 mg/kg. MDL-27531 promotes the binding of benzodiazepine antagonist Ro 15-1788 to cerebral cortex of mice without changing GABA levels. MDL-27531 can be studied in research on reflex control dysfunction[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H302-H315-H319-H335

• Target :

  Glycine Receptor (GlyR)

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Smiles :

  O=S(=O)(C1=NN=C(C=2C=CC=CC2)N1C)C

• Molecular Formula :

  C10H11N3O2S

• Molecular Weight :

  237.28

• Precautions :

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

• References & Citations :

  [1]Kehne, J. H., et al., (1992) . MDL 27,531 selectively reverses strychnine-induced seizures in mice. British journal of pharmacology, 106 (4), 910-916.|[2]Kehne, J. H., et al., (1992) . MDL 27,531 reduces spontaneous hindlimb contractions in rats with chronic transections of the spinal cord. Neuroscience letters, 147 (1), 101-105.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [116850-44-3]